[Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease].
The dose-effect relation and duration of action of 10 mg, 20 mg, 40 mg, and 80 mg ridazolol on ischemic ST-segment depression in exercise-ECG were determined in a randomized, double-blind, acute, cross-over study of 15 patients with confirmed coronary artery disease and reproducible ST-segment depression. Maximal reduction of ST-segment depression in comparison to placebo during constant exercise was 0.16 vs. 0.25 mm (n.s.) after 10 mg, 0.09 vs. 0.25 mm (p less than 0.01) after 20 mg, 0.11 vs. 0.25 mm (p less than 0.01) after 40 mg, and 0.07 vs. 0.25 mm (p less than 0.01) after 80 mg ridazolol. A remarkable reduction of ST-segment depression under placebo was seen in the third and fifth hours after application. Systolic blood pressure under exercise was reduced significantly after 80 mg ridazolol (145 vs. 176 mm Hg; (p less than 0.05) over a period of 5 h. Heart-rate was reduced significantly after 80 mg ridazolol (102 vs. 131/min; p less than 0.05) for 5 h. Rate-pressure product after 20 mg (174 vs. 234 mm Hg/min; p less than 0.01), 40 mg (169 vs. 234 mm Hg/min; p less than 0.01), and 80 mg (153 vs. 234 mm Hg/min; p less than 0.01) ridazolol was reduced significantly over 3 to 5 h. 20, 40 and 80 mg ridazolol show a good antianginal and antihypertensive efficacy. Blood pressure and heart-rate under exercise were significantly reduced over 5 h. In contrast, improvement of ST-segment depression only lasted 1 h. Ridazolol was well tolerated.
Fach
W A
WA
Medizinische Klinik I, Stadtkrankenhaus Hanau.
Starke
E
E
Becker
H J
HJ
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects*; D005080:Exercise Test / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000008:administration & dosage*
D000319:Adrenergic beta-Antagonists; D011724:Pyridazines; C055942:ridazolol
Wirkdauer und Dosis-Wirkungs-Beziehung von Ridazolol bei Patienten mit koronarer Herzkrankheit.